Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 13/20 | 0.56 |
| ▸ | ACACA | Q13085 | 10/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CASR | P41180 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473012 | 0.94 | MEN1 (0.54) | ACACBACACAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12126556 | 0.92 | CYP3A4 (0.59) | ACACBACACAMEN1KMT2ACYP3A4 | |
| SCHEMBL12537090 | 0.89 | CYP3A4 (0.56) | MEN1KMT2ACYP3A4CYP2D6CASR | |
| SCHEMBL16557180 | 0.89 | CYP3A4 (0.56) | MEN1KMT2ACYP3A4CYP2D6CASR | |
| SCHEMBL677559 | 0.87 | RARB (0.58) | MEN1KMT2ACYP3A4CYP2D6NPC1 | |
| SCHEMBL12537108 | 0.87 | RARB (0.58) | MEN1KMT2ACYP3A4CYP2D6NPC1 | |
| SCHEMBL17946790 | 0.87 | RARB (0.58) | MEN1KMT2ACYP3A4CYP2D6NPC1 | |
| SCHEMBL18314262 | 0.87 | RARB (0.58) | MEN1KMT2ACYP3A4CYP2D6NPC1 | |
| SCHEMBL5018762 | 0.86 | MEN1 (0.59) | MEN1KMT2ACYP3A4CYP2D6NPC1 | |
| SCHEMBL9152649 | 0.85 | CYP3A4 (0.63) | ACACBACACAMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110130349-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-7838548-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20090186855-A1 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-7550501-B2 | Compounds and methods for treating toll-like receptor 2-related diseases and conditions | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | EISAI CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| US-7202234-B2 | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions | EISAI CO., LTD. (JP) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ACACB 1694/4885ACACA 2556/4885MEN1 4590/4885 |
| US-20090186855-A1 | COMPOUNDS AND METHODS FOR TREATING TOLL-LIKE RECEPTOR 2-RELATED DISEASES AND CONDITIONS | TLR2, TLR6, TLR3 | ACACB 183/4885ACACA 437/4885MEN1 4397/4885 |
| US-20070167409-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | TLR2, TLR6, TLR3 | ACACB 183/4885ACACA 437/4885MEN1 4397/4885 |
| US-20110130349-A1 | Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions | TLR2, TLR6, TLR3 | ACACB 183/4885ACACA 437/4885MEN1 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.